|
|
|
| The Progress in the Development of COVID-19 Vaccine |
LIAO Xiao-yan1,CHEN Li-li1,2,**( ) |
1 College of Public Health, University of South China, Hengyang, Hunan 421001,China
2 Hengyang Engineering Technology Research Center for Spot Rapid Diagnosis for 2019-nCoV, Hengyang 421001, China |
|
|
|
Abstract Breaking out in Wuhan, China at the end of year 2019, coronavirus disease 2019 (COVID-19) rapidly spread around the world. It was listed as a “public health emergency of international concern” by WHO and has caused incalculable damage to human health and economic development. Humans are generally susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that causes COVID-19. In the lack of specific drugs and treatments, vaccination is the most effective and economical way to prevent and control COVID-19. At present, the vaccines against SARS-CoV-2 are being developed in many countries, which work together to cope with the epidemic. This paper mainly reviews the research advances in the vaccines against SARS-CoV-2, i.e., inactivated vaccine, viral vector vaccine, genetic engineering recombinant subunit vaccine, and nucleic acid vaccine.
|
|
Received: 22 July 2020
Published: 14 January 2021
|
|
|
|
Corresponding Authors:
Li-li CHEN
E-mail: chlili720612@163.com
|
|
|
| [1] |
Wen X T, Hou L T, Fang F C. Epidemic update and risk assessment of 2019 novel coronavirus-China. China CDC Weekly, 2020,2(6):83-86.
doi: 10.46234/ccdcw2020.024
|
|
|
| [2] |
杨利敏, 田德雨, 刘文军. 新型冠状病毒疫苗研究策略分析. 生物工程学报, 2020,36(04):593-604.
|
|
|
| [2] |
Yang L M, Tian D Y, Liu W J. Strategies for vaccine development of COVID-19. Chin J Biotech, 2020,36(04):593-604.
|
|
|
| [3] |
Zhu N, Zhang D Y, Wang W L, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020,382(8):727-733.
pmid: 31978945
|
|
|
| [4] |
Zhou P, Yang X L, Wang X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020,579(7798):270-273.
pmid: 32015507
|
|
|
| [5] |
Lu R J, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020,395(10224):565-574.
pmid: 32007145
|
|
|
| [6] |
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020,579(7798):265-269.
pmid: 32015508
|
|
|
| [7] |
Chan J F, Kok K H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 2020,9(1):221-236.
doi: 10.1080/22221751.2020.1719902
pmid: 31987001
|
|
|
| [8] |
贾明, 王虹, 宋春利, 等. 新型冠状病毒肺炎文献整理及研究概述. 陕西医学杂志, 2020,49(3):259-263+266.
|
|
|
| [8] |
Jia M, Wang H, Song C L, et al. A summary of COVID-19’s literature arrangement and research. Shaanxi Medical Journal, 2020,49(3): 259-263+266.
|
|
|
| [9] |
詹菁, 刘倩, 张雨竹, 等. 新型冠状病毒2019-nCoV的一些初步认识. 环境化学, 2020,39(2):283-291.
|
|
|
| [9] |
Zhan J, Liu Q, Zhang Y Z, et al. Preliminary understanding of the novel coronavirus 2019-nCoV. Environmental Chemistry, 2020,39(2):283-291.
|
|
|
| [10] |
Park W B, Kwon N J, Choi S J, et al. Virus isolation from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci, 2020,35(7):84-88.
|
|
|
| [11] |
Du L Y, Yang Y, Zhou Y S, et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets, 2017,21(2):131-143.
pmid: 27936982
|
|
|
| [12] |
白仲虎, 昕然, 王荣斌. 哺乳动物细胞生产人用灭活疫苗相关技术进展. 中国细胞生物学学报, 2019,41(10):1986-1993.
|
|
|
| [12] |
Bai Z H, Xin R, Wang R B. Review of industrialized production technology of human inactivated vaccine based on mammalian cell culture. Chin J Cell Bio, 2019,41(10):1986-1993.
|
|
|
| [13] |
Gao Q, Bao L L, Mao H Y, et al. Development of an inactivated vaccine for SARS-CoV-2. Science, 2020,369(6499):77-81.
doi: 10.1126/science.abc1932
pmid: 32376603
|
|
|
| [14] |
International Clinical Trials Registry Platform. Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection(COVID-19)-full text view Clinical Trials.Gov. [2020-10-29]. https://clinical trials. Gov/ct2/show/NT04352608?term=S-inovac&cntry=CN&draw=2.
|
|
|
| [15] |
International Clinical Trials Registry Platform. Clinical trial of efficacy and safety of Sinovac’s adsorbed COVID-19(inactivated) vaccine in healthcare professionals-full text viewClinicalTrials.gov. [2020-10-29]. https://clinicaltrials.gov/ct2/show/NCT04456595?term=v- accine&cond=covid-19&draw=2#contacts.
|
|
|
| [16] |
Wang H, Zhang Y T, Huang B Y, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell, 2020,182(1):1-19.
pmid: 32649872
|
|
|
| [17] |
中国临床试验注册中心. 评价新型冠状病毒灭活疫苗(2019-CoV)(Vero细胞)在3岁及以上健康人群中接种的安全性和免疫原性的随机、双盲、安慰剂平行对照 Ⅰ/Ⅱ 期临床试验. [2020-10-29]. http://www.chictr.org.cn/showproj.aspx?proj=53003.
|
|
|
| [17] |
Chinese Clinical Trial Registry. Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial. [2020-05-04]. http://www.chictr.org.cn/showproj.aspx?proj=53003.
|
|
|
| [18] |
Xia S L, Duan K, Zhang Y T, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. JAMA, 2020,324(10):951.
doi: 10.1001/jama.2020.15543
pmid: 32789505
|
|
|
| [19] |
国药网. 全球首个新冠灭活疫苗国际临床(Ⅲ期)试验正式启动. [2020/10/29]. http://www.sinopharm.com/s/1223-4126-38313.html,2020-06-24/2020-07-03.
|
|
|
| [19] |
Sinopharm. Commencement ceremony for the phase clinical trial of inactivated COVID-19 vaccine in the united arab emirates. [2020/10/29]. http://www.sinopharm.com/s/1223-4126-38313.html,2020-06-24/2020-07-03.
|
|
|
| [20] |
成传刚, 慕婷, 袁军, 等. 重组病毒载体疫苗研究进展. 中国病毒病杂志, 2018,8(4):318-328.
|
|
|
| [20] |
Cheng C G, Mu T, Yuan J, et al. Research progress on recombinat viral vector vaccines. Chin J Viral Dis, 2018,8(4):318-328.
|
|
|
| [21] |
Tu Y F, Chien C S, Yarmishyn A A, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci, 2020,21(7):2657-2675.
doi: 10.3390/ijms21072657
|
|
|
| [22] |
Vetter V, Denizer G, Friedland LR, et al. Understanding modern-day vaccines: hat you need to know. Ann Med, 2018,50(2):110-120.
pmid: 29172780
|
|
|
| [23] |
Arora N K, Das M K. COVID-19 vaccine development and the way forward. Indian J Public Health, 2020,64:108-111.
doi: 10.4103/ijph.IJPH_520_20
|
|
|
| [24] |
Humphreys I R, Sebastian S. Novel viral vectors in infectious diseases. Immunology, 2018,153(1):1-9.
doi: 10.1111/imm.12829
pmid: 28869761
|
|
|
| [25] |
Doremalen N V, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020,586:578-582.
doi: 10.1038/s41586-020-2608-y
pmid: 32731258
|
|
|
| [26] |
International Clinical Trials Registry Platform. A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers - A phase I/II trial of a candidate COVID-19 vaccine (COV001). [2020-10-29]. who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001072-15-GB.
|
|
|
| [27] |
Zhu F C, Li Y H, Guan X H, et al. Safety, tolerability,immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 2020, 395, (10240):1845-1854.
doi: 10.1016/S0140-6736(20)31208-3
pmid: 32450106
|
|
|
| [28] |
中国临床试验注册中心. 在18周岁及以上健康成人中开展重组新型冠状病毒(2019-nCOV)疫苗(腺病毒载体)随机、双盲、安慰剂对照设计的 Ⅱ 期临床试验. [2020-10-29]. http://www.chictr.org.cn/showproj.aspx?proj=52006.
|
|
|
| [28] |
Chinese Clinical Trial Registry. A randomized, double-blinded, placebo-controlled phase II clinical trial for recombinant novel coronavirus (2019-nCOV) vaccine (adenovirus vector) in healthy adults aged above 18 years. [2020-10-29]. http://www.chictr.org.cn/showproj.aspx?proj=52006.
|
|
|
| [29] |
International Clinical Trials Registry Platform. An open study of the safety, tolerability and immunogenicity of “Gam-COVID-VacLyo” vaccine against COVID-19-full text view-Clinical Trials.gov. [2020-10-29]. https://clinicaltrials.gov/ct2/how/NCT04437875?sterm=vaccine&cond=covid-19&draw=4.
|
|
|
| [30] |
International Clinical Trials Registry Platform. Clinical trial of efficacy, safety, Immunogenicity of Gam-COVID-Vac vaccine against COVID-19-full text view-Clinical Trials. gov. [2020-10-29]. https://clinicaltrials. gov/ct2/ show/NCT04530396? term=vaccine&cond = covid-19&draw = 3.
|
|
|
| [31] |
Mercado N B, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020,586:583-588.
doi: 10.1038/s41586-020-2607-z
pmid: 32731257
|
|
|
| [32] |
International Clinical Trials Registry Platform. A study of Ad26.COV2. S for the prevention of SARS CoV-2 mediated COVID-19 in adult participants-full text veiw-clinicaltrials. gov. [2020-10-29]. https://clinicaltrials.gov/ct2/show/NCT04505722?term=NCT04505722&draw=2&rank=1.
|
|
|
| [33] |
Glasper A. The quest to find an effective vaccine for COVID-19. Br J Nurs, 2020,29(11):644-646.
doi: 10.12968/bjon.2020.29.11.644
pmid: 32516041
|
|
|
| [34] |
Sempowski G D, Saunders K O, Acharya P, et al. Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell, 2020,181(7):1458-1463.
doi: 10.1016/j.cell.2020.05.041
pmid: 32492407
|
|
|
| [35] |
Robson B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput Bio Med, 2020,121:103749.
doi: 10.1016/j.compbiomed.2020.103749
|
|
|
| [36] |
Tian J H, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. bioRxiv, 2020, doi: https://doi.org/10.1101/2020.06.29.178509.
doi: https://doi.org/10.1101/2020.06.29.178509
pmid: 33398270
|
|
|
| [37] |
Cheryl Keech. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. The New England Journal of Medicine. [2020-10-29]. https://www.nejm.org/doi/full/10.1056/NEJMoa2026920.
doi: 10.1056/NEJMe2100295
pmid: 33406335
|
|
|
| [38] |
智飞生物. 智飞生物重组新型冠状病毒疫苗获批临床试验. [2020-10-29]. http://www.zhifeishengwu.com/news/gsyw/qyyw/2020-06-23/444.html.
|
|
|
| [38] |
ZHI FEI Biological. Zhifei biological recombinant COVID-19 vaccine approved into clinical trial. [2020-10-29]. http://www.zhifeishengwu.com/news/gsyw/qyyw/2020-06-23/444.html.
|
|
|
| [39] |
智飞生物. 智飞生物重组新型冠状病毒疫苗启动Ⅱ期临床试验. [2020-10-29]. http://www.zhifeishengwu.com/news/gsyw/qyyw/2020-07-10/448.html.
|
|
|
| [39] |
ZHI FEI Biological. Zhifei biological recombinant COVID-19 vaccine started phase Ⅱ clinical trial. [2020-10-29]. http://www.zhifeishengwu.com/news/gsyw/qyyw/2020-07-10/448.html.
|
|
|
| [40] |
GlaxoSmithKline. Clover Initiates Phase Ⅰ Clinical Trial for COVID-19 Vaccine Candidate. [2020-10-29]. http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=48.
|
|
|
| [41] |
World Health Organization. Draft landscape of COVID-19 candidate vaccines. [2020-10-29]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
|
|
|
| [42] |
Gaudinski M R, Houser K V, Morabito K M, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, 2018,391(10120):552-562.
doi: 10.1016/S0140-6736(17)33105-7
pmid: 29217376
|
|
|
| [43] |
Wu S C. Progress and concept for COVID-19 vaccine development. Biotechnol J, 2020,15(6):2000147.
doi: 10.1002/biot.v15.6
|
|
|
| [44] |
Wang L S, Shi W, Joyce M G, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun, 2015,6:7712.
doi: 10.1038/ncomms8712
pmid: 26218507
|
|
|
| [45] |
International Clinical Trials Registry Platform. A phase 2a, randomized, observer-blind, placebo controlled, dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 SARS-COV-2 vaccine in adults aged 18 years and older. [2020-10-29]. https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04405076.
|
|
|
| [46] |
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity, 2020,52(4):583-589.
doi: 10.1016/j.immuni.2020.03.007
pmid: 32259480
|
|
|
| [47] |
International Clinical Trials Registry Platform. A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19-full text veiw-ClinicalTrials.gov. [2020-10-29]. https://clinicaltrials.gov/ct2/sho-w/NCT04470427?term=vaccine&cond=covid-19&draw=5.
|
|
|
| [48] |
Mulligan M J, Lyke K E, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate(BNT162b1) in adults 18 to 55 years of ages:interim report. medRxiv, https://doi.org/10.1101/2020.06.30.20142570.
doi: 10.1101/2020.12.15.20248214
pmid: 33354690
|
|
|
| [49] |
International Clinical Trials Registry Platform. Phase 1 open-label study to evaluate the safety, tolerability and immunogenicity of INO-4800, a prophylactic vaccine against SARS-CoV-2, administered intradermally followed by electroporation in healthy volunteers. [2020-10-29]. https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04336410.
|
|
|
| [50] |
International Clinical Trials Registry Platform. A phase I/IIa, dose-ranging trial to evaluate safety, tolerability and immunogenicity of INO-4800, a prophylactic vaccine against sars-cov-2, administered intradermally followed by electroporation in healthy volunteers. [2020-10-29]. https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04447781.
|
|
|
| [51] |
Smith T R, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nature communications, 2020,11(1):2601-2613.
doi: 10.1038/s41467-020-16505-0
pmid: 32433465
|
|
|
| [52] |
International Clinical Trials Registry Platform. A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above. [2020-10-29]. https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000034112.
|
|
|
| [53] |
杨静. 新冠病毒mRNA疫苗研究获突破. 上海科技报, 2020,41(5):64-68.
|
|
|
| [53] |
Yang J. COVID-19 mRNA vaccine made a breakthrough. Shanghai Science and Technology News, 2020,41(5):64-68.
|
|
|
| [54] |
张琳, 李燕, 安志杰. 新型冠状病毒mRNA疫苗研发进展. 中国疫苗和免疫. (2020-05-26) [2020-06-29]. http://kns.cnki.net/kcms/detail/11.5517.R.20200525.1816.002.html.
|
|
|
| [54] |
Zhang L, Li Y, An Z J. Progress toward development of novel coronavirus mRNA vaccines. Chinese Journal of Vaccines and Immunization. (2020-05-26) [2020-06-29]. http://kns.cnki.net/kcms/detail/11.5517.R.20200525.1816.002.html.
|
|
|
| [55] |
Mullard A. COVID-19 vaccine development pipeline gears up. Lancet, 2020,395(10239):1751-1752.
doi: 10.1016/S0140-6736(20)31252-6
pmid: 32505245
|
|
|
| [56] |
施逸凡. 病毒样颗粒疫苗在疾病防治中的研究进展. [2020-10-29]. http://kns.cnki.net/kcms/detail/22.1126.R.20200930.1207.002.html.
|
|
|
| [56] |
Shi Y F. Research progress of virus-like particles-based vaccines in disease prevention and treatment. [2020-10-29]. http://kns.cnki.net/kcms/detail/22.1126.R.20200930.1207.002.html.
|
|
|
| [57] |
Faiq M A. B-cell engineering: A promising approach towards vaccine development for COVID-19. Med Hypotheses, 2020,144:109948.
doi: 10.1016/j.mehy.2020.109948
pmid: 32516733
|
|
|
| [58] |
Langellotto F, Seiler B T, Yu J Y, et al. A rapidly adaptable biomaterial vaccine for SARS-CoV-2. bioRxiv, 2020, doi: https://doi.org/10.1101/2020.07.07.192203.
doi: https://doi.org/10.1101/2020.07.07.192203
pmid: 33398270
|
|
|
| [59] |
Kim E, Erdos G, Huang S, et al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine, 2020,55:102743.
doi: 10.1016/j.ebiom.2020.102743
pmid: 32249203
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
